VRC5283 Zika Virus Vaccine Description 2022
VRC5283 is a Zika Virus DNA Vaccine candidate. It is composed of a single closed-circular DNA plasmid that encodes with wild type precursor transmembrane M and envelope proteins from the H/PF/2013 strain of ZIKV. The vaccine was developed by the Vaccine Research Center (VRC), NIAID
VRC5283 Zika Virus Vaccine Indication
VRC5283 is a new vaccine candidate that instructs the body to make a small amount of Zika virus protein. The body may use this to build an immune response.
VRC5283 Zika Virus Vaccine Dosage
The vaccine is supplied in single-dose vials at a concentration of 4 mg/mL. ZIKV DNA vaccine dose will be 4 mg administered as an intramuscular (IM) injection in the deltoid muscle.
VRC5283 Zika Virus Vaccine News 2017 - 2022
December 4, 2017 - Gene-based Zika vaccine is safe and immunogenic in healthy adults
VRC5283 Zika Virus Vaccine Clinical Trials
VRC5283 has completed clinical trials